SCHEMBL24714348

SCHEMBL24714348

CCSc1cc(=O)c2cc(C(=O)OC)cc(C(C)O)c2o1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.35
▸ ALDH1A1 P00352 4/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ HSD17B10 Q99714 3/20 0.34
▸ TSHR P16473 1/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ TP53 P04637 1/20 0.34
▸ TNKS O95271 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ CCNE2 O96020 1/20 0.33
▸ CDK1 P06493 1/20 0.33
▸ CDK4 P11802 1/20 0.33
▸ CCNB1 P14635 1/20 0.33
▸ CCND1 P24385 1/20 0.33
▸ CCNE1 P24864 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ PIK3CD O00329 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29826476 1.00 KDM4E (0.35) KDM4EALDH1A1ALOX15HSD17B10TSHR
SCHEMBL24713633 0.92 TNKS (0.36) KDM4EALDH1A1ALOX15HSD17B10TSHR
SCHEMBL12666555 0.90 KDM4E (0.35) KDM4EALDH1A1ALOX15HSD17B10TSHR
SCHEMBL30768042 0.89 KDM4E (0.34) KDM4EALDH1A1ALOX15HSD17B10TSHR
SCHEMBL1639065 0.82 PIK3CB (0.52) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL1637326 0.82 CSNK2A2 (0.37) KDM4EALDH1A1ALOX15HSD17B10TSHR
SCHEMBL23887051 0.82 PIK3CA (0.39) CCNE2CDK1CDK4CCNB1CCND1
SCHEMBL30064040 0.82 PIK3CA (0.39) CCNE2CDK1CDK4CCNB1CCND1
SCHEMBL24713822 0.81 KDM4E (0.35) KDM4EALDH1A1ALOX15HSD17B10TSHR
SCHEMBL23886969 0.81 CCNE2 (0.35) CCNE2CDK1CDK4CCNB1CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166617-A1 PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF GEODE THERAPEUTICS INC (US) 2024-05-23 — — US disclosed
CN-117615763-A Phosphoinositide 3 kinase beta inhibitor, composition and preparation method thereof 健道生物医药有限公司 2024-02-27 — — CN disclosed
WO-2022164812-A1 PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF GEODE THERAPEUTICS INC. (US) 2022-08-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166617-A1 PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF PIK3CA, PIK3CB, PI4KA KDM4E 1629/4885ALDH1A1 4729/4885ALOX15 4258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback